AU2017337753B2 - Non-genetic modification of enveloped viruses - Google Patents

Non-genetic modification of enveloped viruses Download PDF

Info

Publication number
AU2017337753B2
AU2017337753B2 AU2017337753A AU2017337753A AU2017337753B2 AU 2017337753 B2 AU2017337753 B2 AU 2017337753B2 AU 2017337753 A AU2017337753 A AU 2017337753A AU 2017337753 A AU2017337753 A AU 2017337753A AU 2017337753 B2 AU2017337753 B2 AU 2017337753B2
Authority
AU
Australia
Prior art keywords
virus
peptide
tumor
seq
cpp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017337753A
Other languages
English (en)
Other versions
AU2017337753A1 (en
Inventor
Cristian CAPASSO
Vincenzo Cerullo
Erkko YLOSMAKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valo Therapeutics Oy
Original Assignee
Valo Therapeutics Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valo Therapeutics Oy filed Critical Valo Therapeutics Oy
Publication of AU2017337753A1 publication Critical patent/AU2017337753A1/en
Application granted granted Critical
Publication of AU2017337753B2 publication Critical patent/AU2017337753B2/en
Priority to AU2023237201A priority Critical patent/AU2023237201B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2017337753A 2016-09-27 2017-09-06 Non-genetic modification of enveloped viruses Active AU2017337753B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023237201A AU2023237201B2 (en) 2016-09-27 2023-09-29 Non-genetic modification of enveloped viruses

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1616365.1A GB201616365D0 (en) 2016-09-27 2016-09-27 Non-genetic modification of enveloped viruses
GB1616365.1 2016-09-27
PCT/EP2017/072366 WO2018059896A1 (en) 2016-09-27 2017-09-06 Non-genetic modification of enveloped viruses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023237201A Division AU2023237201B2 (en) 2016-09-27 2023-09-29 Non-genetic modification of enveloped viruses

Publications (2)

Publication Number Publication Date
AU2017337753A1 AU2017337753A1 (en) 2019-03-21
AU2017337753B2 true AU2017337753B2 (en) 2023-09-28

Family

ID=57539741

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017337753A Active AU2017337753B2 (en) 2016-09-27 2017-09-06 Non-genetic modification of enveloped viruses
AU2023237201A Active AU2023237201B2 (en) 2016-09-27 2023-09-29 Non-genetic modification of enveloped viruses

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023237201A Active AU2023237201B2 (en) 2016-09-27 2023-09-29 Non-genetic modification of enveloped viruses

Country Status (12)

Country Link
US (1) US10982194B2 (cg-RX-API-DMAC7.html)
EP (1) EP3519565A1 (cg-RX-API-DMAC7.html)
JP (2) JP7258746B2 (cg-RX-API-DMAC7.html)
KR (1) KR102599401B1 (cg-RX-API-DMAC7.html)
CN (1) CN109890957A (cg-RX-API-DMAC7.html)
AU (2) AU2017337753B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019005825A2 (cg-RX-API-DMAC7.html)
CA (1) CA3035104A1 (cg-RX-API-DMAC7.html)
GB (1) GB201616365D0 (cg-RX-API-DMAC7.html)
RU (1) RU2760521C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018059896A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201902388B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907413D0 (en) * 2019-05-24 2019-07-10 Univ Helsinki Viral vector
EP3982980A4 (en) * 2019-06-12 2023-11-29 BioNTech US Inc. NEOANTIGEN COMPOSITIONS AND USES THEREOF
CA3152796A1 (en) * 2019-08-27 2021-03-04 Turnstone Biologics Corp. Methods for inducing an immune response against neoantigens
GB202013834D0 (en) * 2020-09-03 2020-10-21 Valo Therapeutics Oy PeptiVAX therapy
AU2023367780A1 (en) 2022-10-25 2025-03-27 Barinthus Biotherapeutics North America, Inc. Self-assembling nanoparticles

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1108047A1 (en) 1998-08-27 2001-06-20 Aventis Pharma S.A. Targeted adenovirus vectors for delivery of heterologous genes
MXPA01005389A (es) * 1998-11-30 2003-03-27 Cytos Biotechnology Ag Presentacion molecular ordenada de antigenos, metodos de preparacion y uso.
CN1477964A (zh) * 1999-04-15 2004-02-25 应用病毒治疗肿瘤
KR100773109B1 (ko) 1999-05-06 2007-11-02 웨이크 포리스트 유니버시티 면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법
CA2390081C (en) * 1999-10-29 2011-07-05 University Of Southern California Modified viral surface proteins which bind to cells of tumor vasculature
MXPA04005382A (es) * 2001-11-07 2005-02-24 Mannkind Corp Vectores de expresion que codifican epitopes de antigenos asociados al objetivo y metodos para su diseno.
GB0203285D0 (en) * 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
WO2004000220A2 (en) 2002-06-21 2003-12-31 Genetix Pharmaceuticals, Inc. Methods for purifying viral particles for gene therapy
US20070243170A1 (en) * 2002-10-07 2007-10-18 The University Of Chicago Targeting of Herpes Simplex Virus to Specific Receptors
CN101675993A (zh) * 2003-03-26 2010-03-24 赛托斯生物技术公司 Melan-a肽类似物-病毒样颗粒偶联物
HRP20120845T1 (hr) * 2003-07-02 2012-11-30 Innate Pharma Protutijela za pan-kir2dl nk-receptor i njihova uporaba u dijagnostici i lijeäśenju
US7432045B2 (en) * 2003-12-01 2008-10-07 Wisconsin Alumni Research Foundation Method of inhibiting influenza infection with antiviral peptides
SG149013A1 (en) * 2003-12-17 2009-01-29 Wyeth Corp Immunogenic peptide carrier conjugates and methods of producing same
EP1921149A1 (en) * 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
JP2008136381A (ja) * 2006-11-30 2008-06-19 Japan Health Science Foundation 改変型アデノウイルスベクター及びその作製方法
WO2009117656A2 (en) 2008-03-21 2009-09-24 Vectorlogics,Inc. Capsid-incorporated antigen for novel adenovirus vaccine
NO2700405T3 (cg-RX-API-DMAC7.html) * 2008-05-29 2018-09-01
US10603351B2 (en) * 2008-08-21 2020-03-31 Turnstone Limited Partnership Engineered synergistic oncolytic viral symbiosis
ES2335077B1 (es) 2008-12-30 2011-02-02 Instituto Aragones De Ciencias De La Salud Formulaciones para el recubrimiento y transporte de diversos elementos hacia los tumores.
SG176554A1 (en) * 2009-05-12 2012-01-30 Transgene Sa Method for orthopoxvirus production and purification
RU2013118723A (ru) 2010-09-24 2014-10-27 Онкос Терапьютикс Ой Онколитические аденовирусные векторы, кодирующие моноклональные антитела против ctla-4
US20140140962A1 (en) 2011-04-29 2014-05-22 The Research Foundation Of State University Of New York Viruses modified with unnatural moieties and methods of use thereof
US20140349944A1 (en) * 2013-05-23 2014-11-27 Musc Foundation For Research Development Chaperone-based integrin inhibitors for the treatment of cancer and inflammatory diseases
ES2847305T3 (es) * 2013-08-22 2021-08-02 Univ Pittsburgh Commonwealth Sys Higher Education Terapias inmunooncolíticas
DK3184641T3 (da) * 2013-10-28 2020-08-03 Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education Onkolytisk hsv-vektor
JP6705755B2 (ja) 2014-05-19 2020-06-03 バロ セラピューティクス オイValo Therapeutics Oy 癌ワクチン開発のための改変アデノウイルス

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CRISTIAN CAPASSO ET AL., 'Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma", ONCOIMMUNOLOGY, 2015, Vol. 5, No. 4, Pages 1-11. *

Also Published As

Publication number Publication date
BR112019005825A2 (pt) 2019-06-11
RU2019110407A3 (cg-RX-API-DMAC7.html) 2021-05-13
AU2023237201A1 (en) 2023-12-14
AU2023237201B2 (en) 2025-06-05
RU2760521C2 (ru) 2021-11-26
JP2019532631A (ja) 2019-11-14
KR102599401B1 (ko) 2023-11-06
CA3035104A1 (en) 2018-04-05
ZA201902388B (en) 2020-10-28
JP2023029997A (ja) 2023-03-07
US20200010811A1 (en) 2020-01-09
WO2018059896A1 (en) 2018-04-05
JP7258746B2 (ja) 2023-04-17
EP3519565A1 (en) 2019-08-07
US10982194B2 (en) 2021-04-20
KR20190053260A (ko) 2019-05-17
GB201616365D0 (en) 2016-11-09
AU2017337753A1 (en) 2019-03-21
RU2019110407A (ru) 2020-10-29
CN109890957A (zh) 2019-06-14
NZ751251A (en) 2025-03-28

Similar Documents

Publication Publication Date Title
AU2023237201B2 (en) Non-genetic modification of enveloped viruses
Hamley Peptides for vaccine development
CN1738901B (zh) 用于调变免疫反应的模块化抗原转运蛋白分子(mat分子)和相关的构建体、方法和用途
RS50101B (sr) Farmaceutski preparati za imunomodulaciju
JP2003529319A (ja) HIV−1gp41を標的化する広範に中和する抗体を誘発する方法
KR20080090411A (ko) 면역자극 조성물 및 방법
JP2006257095A (ja) ヘテロダイマーポリペプチド免疫原キャリア組成物および方法
US20190321460A1 (en) Universal influenza vaccine compositions
RU2746021C2 (ru) Иммуноконъюгаты для специфической индукции цитотоксичности т-клеток против клеток-мишеней
Sabatino Medicinal chemistry and methodological advances in the development of peptide-based vaccines: miniperspective
JP2017538754A (ja) 抗原送達系
US8258257B2 (en) Claudin-4 binding peptides, compositions and methods of use
US20260001938A1 (en) Peptide used for immunotherapeutics
CN109758575B (zh) 充分多样的双亲性mhc ii结合多肽、免疫载体微球及其制备方法和应用
Skea et al. The immunotargeting approach to adjuvant-independent immunization with influenza haemagglutinin
US20240226279A1 (en) Human anti-coronavirus peptide vaccines and methods of their use
Maxwell et al. Intranasal self-adjuvanted lipopeptide vaccines elicit high antibody titers and strong cellular responses against SARS-CoV-2
CN119156343A (zh) 搭载肽的载体系统及其用途
Lelièvre et al. Structural Properties of Chimeric Peptides Containing a T‐cell Epitope Linked to a Fusion Peptide and their Importance for in Vivo Induction of Cytotoxic T‐cell Responses
US20240141009A1 (en) Peptide used for immunotherapeutics
Dettin et al. Design, synthesis and CD4 binding studies of a fluorescent analogue of a peptide that enhances HIV‐1 infectivity
Fletcher et al. of a synthetic peptide conjugate enabling endogenous antibody binding to promote innate receptor engagement
Ladjevardi et al. Erika AK Fletcher, Robert A. Cordfunke, 3, 13 Aikaterini Nasi, Gunilla Törnqvist, Rob RPM Valentijn, 5 Anna Bergqvist, 4 Marita Westhrin, 4 Wenche Rasch, 4 Frida Lindqvist, Inken Dillmann, Martin Lord, Neanke Bouwman, 5 Jacques J. Neefjes, 6 Kees LMC Franken, 7 Stephanie McArdle, 8 Murrium Ahmad, 8 Silvia Johansson, 9, 10 Ferry Ossendorp, 3 Michael Haggman, 10, 11 Maria Lampinen, Gustav Ullenhag, 9, 10
CN116528882A (zh) 用于免疫治疗剂的肽
WO2022049002A1 (en) Peptivax therapy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)